Europe to boost cooperation with international partners on generics
Posted: 7 August 2014 | | No comments yet
European system to be used as model to facilitate assessment of medicines…
The European Union’s decentralised procedure is being used as a model to accelerate the assessment of applications for generic medicines as part of the International Generic Drug Regulators Pilot (IGDRP).
The European Union (EU) is leading an international pilot project through which, upon request from a generic pharmaceutical company, it will share the assessment reports generated as part of the decentralised procedure in real time with collaborating regulatory agencies outside the EU.
By offering to share its assessment reports, the EU aims to reinforce collaboration and information-sharing between regulatory authorities across the world, contributing to facilitating and strengthening the scientific assessment process for medicines. This should enable medicines to be authorised in different territories in a coordinated way at approximately the same time.
The first phase of the pilot project will involve the EU, Australia, Canada, Chinese Taipei and Switzerland.
Other members of the IGDRP may decide to take part in the pilot programme at a later stage. These include Brazil, China, Japan, Korea, Mexico, New Zealand, Russia, Singapore and South Africa. The European Directorate for the Quality of Medicines & Healthcare (EDQM) and the World Health Organization (WHO) participate as observers.
Further information about how to participate in the pilot programme can be found on the website of the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh).
This initiative is one of the work packages of the IGDRP. Other areas of cooperation in which the EU is involved include work sharing possibilities in the area of active substance master file, inspection of sites conducting bioequivalence and bio-analytical studies and information sharing on pharmaceutical quality issues.
The IGDRP was launched in April 2012 to promote collaboration and convergence in generic medicines regulatory programmes in order to address the challenges posed by increasing workloads, globalisation and complexity of scientific issues.
